Nucleoporins and nucleocytoplasmic transport in hematologic malignancies

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 3-10

  Takeda, Akiko ^a   Yaseen, Nabeel R ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; CRM1; Leukemia; Nuclear export; Nucleocytoplasmic transport; Nucleoporin; NUP214; NUP98; XPO1

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; EXPORTIN 1 INHIBITOR; HYBRID PROTEIN; LEPTOMYCIN B; NUCLEOPORIN; NUCLEOPORIN 214; NUCLEOPORIN 98; SELINEXOR; UNCLASSIFIED DRUG; NUCLEAR PORE COMPLEX PROTEIN 98; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELLULAR DISTRIBUTION; CHROMOSOME REARRANGEMENT; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HUMAN; INTERNAL TANDEM DUPLICATION; MITOSIS; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; ACTIVE TRANSPORT; ANIMAL; DRUG EFFECTS; GENETICS; HEMATOLOGIC DISEASE; METABOLISM;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; MITOSIS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84904510701     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.02.009     Document Type: Review

References (167)

1. Scandura J.M., Boccuni P., Cammenga J., Nimer S.D. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene 2002, 21:3422-3444.
2. Raices M., D'Angelo M.A. Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions. Nat Rev Mol Cell Biol 2012, 13:687-699.
3. Chatel G., Fahrenkrog B. Dynamics and diverse functions of nuclear pore complex proteins. Nucleus 2012, 3:162-171.
4. Chatel G., Fahrenkrog B. Nucleoporins: leaving the nuclear pore complex for a successful mitosis. Cell Signal 2011, 23:1555-1562.
5. Capelson M., Doucet C., Hetzer M.W. Nuclear pore complexes: guardians of the nuclear genome. Cold Spring Harb Symp Quant Biol 2010, 75:585-597.
6. Hutten S., Kehlenbach R.H. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007, 17:193-201.
7. Bain B.J. Leukaemia diagnosis 1999, Blackwell Science, London. 2nd ed.
8. Romana S.P., Radford-Weiss I., Ben Abdelali R., Schluth C., Petit A., Dastugue N., et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 2006, 20:696-706.
9. Tosi S., Ballabio E., Teigler-Schlegel A., Boultwood J., Bruch J., Harbott J. Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia. Genes Chromosomes Cancer 2005, 44:225-232.
10. Nebral K., Schmidt H.H., Haas O.A., Strehl S. NUP98 Is Fused to Topoisomerase (DNA) II{beta} 180kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15). Clin Cancer Res 2005, 11:6489-6494.
11. van Zutven L.J., Onen E., Velthuizen S.C., van Drunen E., von Bergh A.R., van den Heuvel-Eibrink M.M., et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 2006, 45:437-446.
12. Panagopoulos I., Kerndrup G., Carlsen N., Strombeck B., Isaksson M., Johansson B. Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol 2007, 136:294-296.
13. Reader J.C., Meekins J.S., Gojo I., Ning Y. A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 2007, 21:842-844.
14. Pan Q., Zhu Y.J., Gu B.W., Cai X., Bai X.T., Yun H.Y., et al. A new fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation. Oncogene 2008, 27:3414-3423.
15. Ishikawa M., Yagasaki F., Okamura D., Maeda T., Sugahara Y., Jinnai I., et al. A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia. Int J Hematol 2007, 86:238-245.
16. Jankovic D., Gorello P., Liu T., Ehret S., La Starza R., Desjobert C., et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood 2008, 111:5672-5682.
17. Yamamoto M., Kakihana K., Kurosu T., Murakami N., Miura O. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet 2005, 157:104-108.
18. Gorello P., Brandimarte L., La Starza R., Pierini V., Bury L., Rosati R., et al. t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. Haematologica 2008, 93:1398-1401.
19. Kaltenbach S., Soler G., Barin C., Gervais C., Bernard O.A., Penard-Lacronique V., et al. A NUP98-MLL fusion in human acute myeloblastic leukemia. Blood 2010, 116:2332-2335.
20. Petit A., Ragu C., Della-Valle V., Mozziconacci M.J., Lafage-Pochitaloff M., Soler G., et al. NUP98-HMGB3: a novel oncogenic fusion. Leukemia 2010, 24:654-658.
21. Slape C., Lin Y.W., Hartung H., Zhang Z., Wolff L., Aplan P.D. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men. J Natl Cancer Inst Monogr 2008, 2008:64-68.
22. Such E., Cervera J., Valencia A., Barragan E., Ibanez M., Luna I., et al. A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 2011, 117:242-245.
23. Arber D.A., Brunning R.D., Le Beau M.M., Falini B., Vardiman J.W., Porwit A., et al. Acute myeloid leukemia with recurrent genetic abnormalities. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 110-123. International Agency for Research on Cancer, Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, A. et (Eds.).
24. Chi Y., Lindgren V., Quigley S., Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008, 132:1835-1837.
25. Garcon L., Libura M., Delabesse E., Valensi F., Asnafi V., Berger C., et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005, 19:1338-1344.
26. Chou W.C., Chen C.Y., Hou H.A., Lin L.I., Tang J.L., Yao M., et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia 2009, 23:1303-1310.
27. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
28. Yamamoto K., Nakamachi Y., Yakushijin K., Funakoshi Y., Okamura A., Kawano S., et al. Expression of the novel NUP98/PSIP1 fusion transcripts in myelodysplastic syndrome with t(9;11)(p22;p15). Eur J Haematol 2012, 88:244-248.
29. Lisboa S., Cerveira N., Bizarro S., Correia C., Vieira J., Torres L., et al. POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). Mol Cancer 2013, 12:5.
30. Gough S.M., Slape C.I., Aplan P.D. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011, 118:6247-6257.
31. Borrow J., Shearman A.M., Stanton V.P., Becher R., Collins T., Williams A.J., et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996, 12:159-167.
32. Nakamura T., Largaespada D.A., Lee M.P., Johnson L.A., Ohyashiki K., Toyama K., et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996, 12:154-158.
33. Huang S.Y., Tang J.L., Liang Y.J., Wang C.H., Chen Y.C., Tien H.F. Clinical, haematological and molecular studies in patients with chromosome translocation t(7;11): a study of four Chinese patients in Taiwan. Br J Haematol 1997, 96:682-687.
34. Kwong Y.L., Pang A. Low frequency of rearrangements of the homeobox gene HOXA9/t(7;11) in adult acute myeloid leukemia. Genes Chromosomes Cancer 1999, 25:70-74.
35. Hollink I.H., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T., Pratcorona M., Abbas S., Kuipers J.E., et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011, 118:3645-3656.
36. de Rooij J.D., Hollink I.H., Arentsen-Peters S.T., van Galen J.F., Berna Beverloo H., Baruchel A., et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 2013, 27:2280-2288.
37. Chung K.Y., Morrone G., Schuringa J.J., Plasilova M., Shieh J.H., Zhang Y., et al. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res 2006, 66:11781-11791.
38. Yassin E.R., Sarma N.J., Abdul-Nabi A.M., Dombrowski J., Han Y., Takeda A., et al. Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9. PLoS ONE 2009, 4:e6719.
39. Takeda A., Goolsby C., Yaseen N.R. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res 2006, 66:6628-6637.
40. Yassin E.R., Abdul-Nabi A.M., Takeda A., Yaseen N.R. Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif. Leukemia 2010, 24:1001-1011.
41. Pineault N., Buske C., Feuring-Buske M., Abramovich C., Rosten P., Hogge D.E., et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 2003, 101:4529-4538.
42. Hirose K., Abramovich C., Argiropoulos B., Humphries R.K. Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor. Oncogene 2008, 27:6056-6067.
43. Gurevich R.M., Aplan P.D., Humphries R.K. NUP98-topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. Blood 2004, 104:1127-1136.
44. Wang G.G., Cai L., Pasillas M.P., Kamps M.P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007, 9:804-812.
45. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009, 459:847-851.
46. Lin Y.W., Slape C., Zhang Z., Aplan P.D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005, 106:287-295.
47. Kroon E., Thorsteinsdottir U., Mayotte N., Nakamura T., Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J 2001, 20:350-361.
48. Calvo K.R., Sykes D.B., Pasillas M.P., Kamps M.P. NUP98-HOXA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene 2002, 21:4247-4256.
49. Slape C., Chung Y.J., Soloway P.D., Tessarollo L., Aplan P.D. Mouse embryonic stem cells that express a NUP98-HOXD13 fusion protein are impaired in their ability to differentiate and can be complemented by BCR-ABL. Leukemia 2007, 21:1239-1248.
50. Ahuja H.G., Popplewell L., Tcheurekdjian L., Slovak M.L. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia. Genes Chromosomes Cancer 2001, 30:410-415.
51. Taketani T., Taki T., Nakamura T., Kobayashi Y., Ito E., Fukuda S., et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 2010, 24:1975-1977.
52. Iwasaki M., Kuwata T., Yamazaki Y., Jenkins N.A., Copeland N.G., Osato M., et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. Blood 2005, 105:784-793.
53. Slape C., Hartung H., Lin Y.W., Bies J., Wolff L., Aplan P.D. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res 2007, 67:5148-5155.
54. Pineault N., Abramovich C., Ohta H., Humphries R.K. Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1. Mol Cell Biol 2004, 24:1907-1917.
55. Palmqvist L., Argiropoulos B., Pineault N., Abramovich C., Sly L.M., Krystal G., et al. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood 2006, 108:1030-1036.
56. Dash A.B., Williams I.R., Kutok J.L., Tomasson M.H., Anastasiadou E., Lindahl K., et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 2002, 99:7622-7627.
57. Mayotte N., Roy D.C., Yao J., Kroon E., Sauvageau G. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood 2002, 100:4177-4184.
58. Greenblatt S., Li L., Slape C., Nguyen B., Novak R., Duffield A., et al. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood 2012, 119:2883-2894.
59. Kraemer D., Wozniak R.W., Blobel G., Radu A. The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm. Proc Natl Acad Sci USA 1994, 91:1519-1523.
60. Alsabeh R., Brynes R.K., Slovak M.L., Arber D.A. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 1997, 107:430-437.
61. Oyarzo M.P., Lin P., Glassman A., Bueso-Ramos C.E., Luthra R., Medeiros L.J. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004, 122:348-358.
62. Slovak M.L., Gundacker H., Bloomfield C.D., Dewald G., Appelbaum F.R., Larson R.A., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20:1295-1297.
63. von Lindern M., Breems D., van Baal S., Adriaansen H., Grosveld G. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 1992, 5:227-234.
64. Liu F., Gao L., Jing Y., Xu Y.Y., Ding Y., Zhou M.H., et al. Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia. Leuk Lymphoma 2013, 54:1521-1526.
65. Lee E.Y., Park T.S., Kim M.J., Chang M.H., Cho E.H., Park S.J., et al. Detection of SET-NUP214 rearrangement using multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) in acute leukemias: a case report and literature review on a Korean case series. Ann Hematol 2012, 91:1135-1138.
66. Lee S.G., Park T.S., Cho S.Y., Lim G., Park G.J., Oh S.H., et al. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature. Ann Clin Lab Sci 2011, 41:267-272.
67. Chae H., Lim J., Kim M., Park J., Kim Y., Han K., et al. Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement. Ann Hematol 2012, 91:193-201.
68. Li W.J., Cui L., Gao C., Zhao X.X., Liu S.G., Xing Y.P., et al. MRD analysis and treatment outcome in three children with SET-NUP214-positive hematological malignancies. Int J Lab Hematol 2011, 33:e25-e27.
69. von Lindern M., Fornerod M., Soekarman N., van Baal S., Jaegle M., Hagemeijer A., et al. Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene. Baillieres Clin Haematol 1992, 5:857-879.
70. Kim J., Lee S.G., Song J., Kim S.J., Rha S.Y., Lee K.A., et al. Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Cancer Genet Cytogenet 2010, 201:73-80.
71. Gorello P., La Starza R., Di Giacomo D., Messina M., Puzzolo M.C., Crescenzi B., et al. SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia. Haematologica 2010, 95:2161-2163.
72. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.
73. Hagemeijer A., Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010, 49:299-308.
74. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
75. Eyre T., Schwab C.J., Kinstrie R., McGuire A.K., Strefford J., Peniket A., et al. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012, 120:4441-4443.
76. Graux C., Stevens-Kroef M., Lafage M., Dastugue N., Harrison C.J., Mugneret F., et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:125-133.
77. Oancea C., Ruster B., Henschler R., Puccetti E., Ruthardt M. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 2010, 24:1910-1919.
78. Boer J., Bonten-Surtel J., Grosveld G. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol 1998, 18:1236-1247.
79. Sanden C., Ageberg M., Petersson J., Lennartsson A., Gullberg U. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. BMC Cancer 2013, 13:440.
80. Saito S., Nouno K., Shimizu R., Yamamoto M., Nagata K. Impairment of erythroid and megakaryocytic differentiation by a leukemia-associated and t(9;9)-derived fusion gene product, SET/TAF-Ibeta-CAN/Nup214. J Cell Physiol 2008, 214:322-333.
81. Ozbek U., Kandilci A., van Baal S., Bonten J., Boyd K., Franken P., et al. SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol 2007, 171:654-666.
82. Radu A., Moore M.S., Blobel G. The peptide repeat domain of nucleoporin Nup98 functions as a docking site in transport across the nuclear pore complex. Cell 1995, 81:215-222.
83. Griffis E.R., Altan N., Lippincott-Schwartz J., Powers M.A. Nup98 is a mobile nucleoporin with transcription-dependent dynamics. Mol Biol Cell 2002, 13:1282-1297.
84. Fontoura B.M., Dales S., Blobel G., Zhong H. The nucleoporin Nup98 associates with the intranuclear filamentous protein network of TPR. Proc Natl Acad Sci USA 2001, 98:3208-3213.
85. Fornerod M., Boer J., van Baal S., Jaegle M., von Lindern M., Murti K.G., et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995, 10:1739-1748.
86. De Keersmaecker K., Rocnik J.L., Bernad R., Lee B.H., Leeman D., Gielen O., et al. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell 2008, 31:134-142.
87. Fontoura B.M., Blobel G., Matunis M.J. A conserved biogenesis pathway for nucleoporins: proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96. J Cell Biol 1999, 144:1097-1112.
88. Vasu S., Shah S., Orjalo A., Park M., Fischer W.H., Forbes D.J. Novel vertebrate nucleoporins Nup133 and Nup160 play a role in mRNA export. J Cell Biol 2001, 155:339-354.
89. Griffis E.R., Xu S., Powers M.A. Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes. Mol Biol Cell 2003, 14:600-610.
90. Takeda A., Sarma N.J., Abdul-Nabi A.M., Yaseen N.R. Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins. J Biol Chem 2010, 285:16248-16257.
91. Moore M.A., Chung K.Y., Plasilova M., Schuringa J.J., Shieh J.H., Zhou P., et al. NUP98 dysregulation in myeloid leukemogenesis. Ann NY Acad Sci 2007, 1106:114-142.
92. Cronshaw J.M., Krutchinsky A.N., Zhang W., Chait B.T., Matunis M.J. Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 2002, 158:915-927.
93. Walde S., Kehlenbach R.H. The part and the whole: functions of nucleoporins in nucleocytoplasmic transport. Trends Cell Biol 2010, 20:461-469.
94. Adams R.L., Wente S.R. Uncovering nuclear pore complexity with innovation. Cell 2013, 152:1218-1221.
95. Hoelz A., Debler E.W., Blobel G. The structure of the nuclear pore complex. Annu Rev Biochem 2011, 80:613-643.
96. Grunwald D., Singer R.H., Rout M. Nuclear export dynamics of RNA-protein complexes. Nature 2011, 475:333-341.
97. Oka M., Asally M., Yasuda Y., Ogawa Y., Tachibana T., Yoneda Y. The mobile FG nucleoporin Nup98 is a cofactor for Crm1-dependent protein export. Mol Biol Cell 2010, 21:1885-1896.
98. Roth P., Xylourgidis N., Sabri N., Uv A., Fornerod M., Samakovlis C. The Drosophila nucleoporin DNup88 localizes DNup214 and CRM1 on the nuclear envelope and attenuates NES-mediated nuclear export. J Cell Biol 2003, 163:701-706.
99. Fornerod M., van Deursen J., van Baal S., Reynolds A., Davis D., Murti K.G., et al. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J 1997, 16:807-816.
100. Bogerd H.P., Echarri A., Ross T.M., Cullen B.R. Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J Virol 1998, 72:8627-8635.
101. Hutten S., Kehlenbach R.H. Nup214 is required for CRM1-dependent nuclear protein export in vivo. Mol Cell Biol 2006, 26:6772-6785.
102. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
103. Kutay U., Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005, 15:121-124.
104. Saito S., Miyaji-Yamaguchi M., Nagata K. Aberrant intracellular localization of SET-CAN fusion protein, associated with a leukemia, disorganizes nuclear export. Int J Cancer 2004, 111:501-507.
105. Bachi A., Braun I.C., Rodrigues J.P., Pante N., Ribbeck K., von Kobbe C., et al. The C-terminal domain of TAP interacts with the nuclear pore complex and promotes export of specific CTE-bearing RNA substrates. RNA 2000, 6:136-158.
106. Blevins M.B., Smith A.M., Phillips E.M., Powers M.A. Complex formation among the RNA export proteins Nup98, Rae1/Gle2 and TAP. J Biol Chem 2003, 278:20979-20988.
107. Levesque L., Bor Y.C., Matzat L.H., Jin L., Berberoglu S., Rekosh D., et al. Mutations in tap uncouple RNA export activity from translocation through the nuclear pore complex. Mol Biol Cell 2006, 17:931-943.
108. Powers M.A., Forbes D.J., Dahlberg J.E., Lund E. The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways. J Cell Biol 1997, 136:241-250.
109. Wang X., Babu J.R., Harden J.M., Jablonski S.A., Gazi M.H., Lingle W.L., et al. The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins. J Biol Chem 2001, 276:26559-26567.
110. Fontoura B.M., Blobel G., Yaseen N.R. The nucleoporin nup98 is a site for GDP/GTP exchange on ran and termination of karyopherin beta 2-mediated nuclear import. J Biol Chem 2000, 275:31289-31296.
111. van Deursen J., Boer J., Kasper L., Grosveld G. G2 arrest and impaired nucleocytoplasmic transport in mouse embryos lacking the proto-oncogene CAN/Nup214. EMBO J 1996, 15:5574-5583.
112. Trotman L.C., Mosberger N., Fornerod M., Stidwill R.P., Greber U.F. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 2001, 3:1092-1100.
113. Xu L., Alarcon C., Col S., Massague J. Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. J Biol Chem 2003, 278:42569-42577.
114. von Moeller H., Basquin C., Conti E. The mRNA export protein DBP5 binds RNA and the cytoplasmic nucleoporin NUP214 in a mutually exclusive manner. Nat Struct Mol Biol 2009, 16:247-254.
115. Katahira J., Strasser K., Podtelejnikov A., Mann M., Jung J.U., Hurt E. The Mex67p-mediated nuclear mRNA export pathway is conserved from yeast to human. EMBO J 1999, 18:2593-2609.
116. Napetschnig J., Kassube S.A., Debler E.W., Wong R.W., Blobel G., Hoelz A. Structural and functional analysis of the interaction between the nucleoporin Nup214 and the DEAD-box helicase Ddx19. Proc Natl Acad Sci USA 2009, 106:3089-3094.
117. Browne S.K., Roesser J.R., Zhu S.Z., Ginder G.D. Differential IFN-gamma stimulation of HLA-A gene expression through CRM-1-dependent nuclear RNA export. J Immunol 2006, 177:8612-8619.
118. Forler D., Rabut G., Ciccarelli F.D., Herold A., Kocher T., Niggeweg R., et al. RanBP2/Nup358 provides a major binding site for NXF1-p15 dimers at the nuclear pore complex and functions in nuclear mRNA export. Mol Cell Biol 2004, 24:1155-1167.
119. Laurell E., Beck K., Krupina K., Theerthagiri G., Bodenmiller B., Horvath P., et al. Phosphorylation of Nup98 by multiple kinases is crucial for NPC disassembly during mitotic entry. Cell 2011, 144:539-550.
120. Cross M.K., Powers M.A. Nup98 regulates bipolar spindle assembly through association with microtubules and opposition of MCAK. Mol Biol Cell 2011, 22:661-672.
121. Jeganathan K.B., Malureanu L., van Deursen J.M. The Rae1-Nup98 complex prevents aneuploidy by inhibiting securin degradation. Nature 2005, 438:1036-1039.
122. Funasaka T., Nakano H., Wu Y., Hashizume C., Gu L., Nakamura T., et al. RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Cell Cycle 2011, 10:1456-1467.
123. Hashizume C., Nakano H., Yoshida K., Wong R.W. Characterization of the role of the tumor marker Nup88 in mitosis. Mol Cancer 2010, 9:119.
124. Guttinger S., Laurell E., Kutay U. Orchestrating nuclear envelope disassembly and reassembly during mitosis. Nat Rev Mol Cell Biol 2009, 10:178-191.
125. Bolhy S., Bouhlel I., Dultz E., Nayak T., Zuccolo M., Gatti X., et al. A Nup133-dependent NPC-anchored network tethers centrosomes to the nuclear envelope in prophase. J Cell Biol 2011, 192:855-871.
126. Xu S., Powers M.A. Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. Mol Biol Cell 2010, 21:1585-1596.
127. Nakano H., Funasaka T., Hashizume C., Wong R.W. Nucleoporin translocated promoter region (Tpr) associates with dynein complex, preventing chromosome lagging formation during mitosis. J Biol Chem 2010, 285:10841-10849.
128. Sarma N.J., Yaseen N.R. Dynein light chain 1 (DYNLT1) interacts with normal and oncogenic nucleoporins. PLoS ONE 2013, 8:e67032.
129. Etchin J., Sun Q., Kentsis A., Farmer A., Zhang Z.C., Sanda T., et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27:66-74.
130. Cheng Y., Holloway M.P., Nguyen K., McCauley D., Landesman Y., Kauffman M.G., et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple negative breast cancer. Mol Cancer Ther 2014, 13:675-686.
131. Forgues M., Difilippantonio M.J., Linke S.P., Ried T., Nagashima K., Feden J., et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 2003, 23:5282-5292.
132. Budhu A.S., Wang X.W. Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1. Cell Cycle 2005, 4:1510-1514.
133. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
134. Arnaoutov A., Azuma Y., Ribbeck K., Joseph J., Boyarchuk Y., Karpova T., et al. Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol 2005, 7:626-632.
135. Wu Z., Jiang Q., Clarke P.R., Zhang C. Phosphorylation of Crm1 by CDK1-cyclin-B promotes Ran-dependent mitotic spindle assembly. J Cell Sci 2013, 126:3417-3428.
136. Knauer S.K., Mann W., Stauber R.H. Survivin's dual role: an export's view. Cell Cycle 2007, 6:518-521.
137. Ruchaud S., Carmena M., Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007, 8:798-812.
138. Kasper L.H., Brindle P.K., Schnabel C.A., Pritchard C.E., Cleary M.L., van Deursen J.M. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 1999, 19:764-776.
139. Bai X.T., Gu B.W., Yin T., Niu C., Xi X.D., Zhang J., et al. Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats. Cancer Res 2006, 66:4584-4590.
140. Mendjan S., Taipale M., Kind J., Holz H., Gebhardt P., Schelder M., et al. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell 2006, 21:811-823.
141. Brown C.R., Kennedy C.J., Delmar V.A., Forbes D.J., Silver P.A. Global histone acetylation induces functional genomic reorganization at mammalian nuclear pore complexes. Genes Dev 2008, 22:627-639.
142. Capelson M., Liang Y., Schulte R., Mair W., Wagner U., Hetzer M.W. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 2010, 140:372-383.
143. Kalverda B., Pickersgill H., Shloma V.V., Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010, 140:360-371.
144. Vaquerizas J.M., Suyama R., Kind J., Miura K., Luscombe N.M., Akhtar A. Nuclear pore proteins nup153 and megator define transcriptionally active regions in the Drosophila genome. PLoS Genet 2010, 6:e1000846.
145. Light W.H., Freaney J., Sood V., Thompson A., D'Urso A., Horvath C.M., et al. A conserved role for human Nup98 in altering chromatin structure and promoting epigenetic transcriptional memory. PLoS Biol 2013, 11:e1001524.
146. Lucchesi J.C., Kelly W.G., Panning B. Chromatin remodeling in dosage compensation. Ann Rev Genet 2005, 39:615-651.
147. Bei L., Lu Y., Eklund E.A. HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. J Biol Chem 2005, 280:12359-12370.
148. Palmqvist L., Pineault N., Wasslavik C., Humphries R.K. Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes. PLoS ONE 2007, 2:e768.
149. Nakamura T., Yamazaki Y., Hatano Y., Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood 1999, 94:741-747.
150. Ghannam G., Takeda A., Camarata T., Moore M.A., Viale A., Yaseen N.R. The oncogene NUP98-HOXA9 induces gene transcription in myeloid cells. J Biol Chem 2004, 279:866-875.
151. He C., Li F., Zhang J., Wu J., Shi Y. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem 2013, 288:4692-4703.
152. Rosati R., La Starza R., Veronese A., Aventin A., Schwienbacher C., Vallespi T., et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99:3857-3860.
153. Taketani T., Taki T., Nakamura H., Taniwaki M., Masuda J., Hayashi Y. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 2009, 190:108-112.
154. Banninger G., Reich N.C. STAT2 nuclear trafficking. J Biol Chem 2004, 279:39199-39206.
155. Kehlenbach R.H., Assheuer R., Kehlenbach A., Becker J., Gerace L. Stimulation of nuclear export and inhibition of nuclear import by a Ran mutant deficient in binding to Ran-binding protein 1. J Biol Chem 2001, 276:14524-14531.
156. McBride K.M., McDonald C., Reich N.C. Nuclear export signal located within the DNA-binding domain of the STAT1transcription factor. EMBO J 2000, 19:6196-6206.
157. Tam W.F., Lee L.H., Davis L., Sen R. Cytoplasmic sequestration of rel proteins by IkappaBalpha requires CRM1-dependent nuclear export. Mol Cell Biol 2000, 20:2269-2284.
158. Ivanova I.A., Dagnino L. Activation of p38- and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation. Oncogene 2007, 26:1147-1154.
159. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006, 281:33095-33106.
160. Harhaj E.W., Sun S.C. Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol Cell Biol 1999, 19:7088-7095.
161. Kehlenbach R.H., Dickmanns A., Gerace L. Nucleocytoplasmic shuttling factors including Ran and CRM1 mediate nuclear export of NFAT In vitro. J Cell Biol 1998, 141:863-874.
162. London C.A., Bernabe L.F., Barnard S., Kisseberth W.C., Borgatti A., Henson M., et al. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS ONE 2014, 9:e87585.
163. Walker C.J., Oaks J.J., Santhanam R., Neviani P., Harb J.G., Ferenchak G., et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013, 122:3034-3044.
164. Ranganathan P., Yu X., Na C., Santhanam R., Shacham S., Kauffman M., et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120:1765-1773.
165. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006, 107:4514-4523.
166. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
167. Chou S.H., Ko B.S., Chiou J.S., Hsu Y.C., Tsai M.H., Chiu Y.C., et al. A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS ONE 2012, 7:e49769.